Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Arthritis Research UK has approved a 5-year renewal of the OA Centre.

The Arthritis Research UK Centre for Osteoarthritis (OA) Pathogenesis was first established in 2013 to identify new targets in the disease and create a seamless pipeline between laboratory discovery and clinical trials.

OA is the most common, yet one of the most neglected diseases of rheumatology, affecting over 8 million people in the UK. As with all diseases, it is important to understand the underlying pathways that drive the condition before drug treatments can be designed.

The Centre has had several successes in this area so far and has built an international reputation which has attracted excellent students, visiting workers and research fellows.

The Centre is delighted to receive further funding from Arthritis Research UK to continue this important work. Professor Tonia Vincent, Director of the Centre said:

"This grant has given us the opportunity to contribute to international efforts to understand early molecular pathways in OA. We are now in a position to move these forward to assess their suitability as targets in human disease. The next 5 years will be an exciting time for all of us and, we hope, a cause for optimism for our millions of OA sufferers."

Over the next five years, the Centre will focus its efforts in select areas of the disease, such as how tissues of the joint respond to injury, and on those areas where the Centre can expect to have the biggest impact, such as discovering new ways to image early damage in OA joints.

Although large scale clinical trials are still a little way off, the Centre believes that by the end of this grant, it will have tested two or three targets in groups of OA patients.

Similar stories

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Leducq Foundation grant boosts cardiovascular research

The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases

A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.

Wellcome Trust Investigator Award for Professor Arnon

Congratulations to Professor Arnon on her successful Wellcome Trust Investigator Award entitled: “Spatiotemporal basis of adaptive immunity in the spleen.”